Skip to main content
. Author manuscript; available in PMC: 2010 Aug 15.
Published in final edited form as: Cancer Res. 2009 Aug 4;69(16):6581–6589. doi: 10.1158/0008-5472.CAN-09-1161

Figure 6.

Figure 6

(A) Zerumbone increased p53 expression. HCT116 cells were treated with various concentration and times as indicated. Whole-cell extracts were prepared and analyzed by Western blotting using p53 antibody. (B) Effect of p53 on zerumbone-induced DR expression. H1299 cells (p53 null cells; left) and HCT116 and p53 variant cells (right) were treated with zerumbone for 24 h. Whole-cell extracts were prepared and analyzed by Western blotting using relevant antibodies. (C) Cells were pretreated with zerumbone for 12 h and exposed to TRAIL for 24 h. Whole-cell extracts were prepared and analyzed by Western blotting using indicated antibodies. (D) HCT116 and bax variant cells were treated with zerumbone for 24 h. Whole-cell extracts were prepared and analyzed by Western blotting using relevant antibodies. Equal protein loading was evaluated by β-actin.